NanoBio Announces Data Presentation on Its Nanoemulsion Adjuvanted RSV Vaccine at IDWeek 2012
ANN ARBOR, Mich. and SAN DIEGO (October 15, 2012) – NanoBio Corporation announced today that results from its nanoemulsion adjuvanted RSV vaccine will be presented at IDWeek 2012™ taking place from Oct. 17-21 in San Diego.
The following presentation will occur on Saturday, Oct. 20 from 12:30 – 2:00 p.m. Pacific Time in Halls F-H of the San Diego Convention Center.
Presentation 1745: “Mucosal administration of nanoemulsion formulated RSV vaccine produces an enhanced Th17 response and reduced airway hyperreactivity.”
During the presentation, NanoBio will share preclinical data on its nanoemulsion adjuvanted intranasal and intramuscular RSV vaccine which demonstrated:
Nanoemulsion-based RSV vaccines administered intranasally and intramuscularly elicit robust immune responses that are qualitatively different yet provide equal protection against RSV challenge.
Mucosal administration of nanoemulsion formulated RSV vaccine produced an enhanced Th17 response associated with reduced airway hyperreactivity.
NanoBio’s RSV vaccine uses nanoemulsion technology as an intranasal and intramuscular adjuvant and delivery system derived from its clinically-validated NanoStat® technology platform.
RSV is a highly contagious viral disease and is one of the most common causes of bronchiolitis and pneumonia. It is the number one cause of childhood hospitalization both in the United States and around the world. Nearly all children are infected with the virus at least once by the age of 2-3 years. The disease is particularly dangerous for premature babies, children with other health conditions and the elderly. Many children develop pulmonary disease and/or asthma from RSV that persists throughout adult life making them susceptible to re-infection. Currently, there are no approved vaccines for RSV, despite tremendous need and widespread interest to develop new therapies.
NanoBio® Corporation is a privately-held biopharmaceutical company focused on developing and commercializing dermatological products, anti-infective treatments and intranasal vaccines derived from its patented NanoStat® technology platform. The company’s lead product candidates are treatments for herpes labialis, onychomycosis, vaginitis, cystic fibrosis and a broad platform of intranasal vaccines. The company’s headquarters and laboratory facilities are located in Ann Arbor, Michigan.